Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100685 · ClinicalTrials.gov registry record · Phase 2
Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
A Phase 2 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00100685 is a Phase 2 study that was terminated before completion, run by Abbott. The registered enrollment target is 48 participants.
The verdict
NCT00100685, a Phase 2 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) and is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
Interventions
- DRUG Volociximab (anti-α5β1 integrin monoclonal antibody)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100685
The ClinicalTrials.gov registry entry for NCT00100685 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Volociximab (anti-α5β1 integrin monoclonal antibody) is the first listed.
NCT00100685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100685 about?
NCT00100685 is a clinical study titled "Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)". This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) and is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.
What is the current status of trial NCT00100685?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2005-01. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00100685?
The interventions under investigation include: Volociximab (anti-α5β1 integrin monoclonal antibody) (DRUG).
Who is sponsoring clinical trial NCT00100685?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.